Search

Your search keyword '"Furtado, Remo H.M."' showing total 26 results

Search Constraints

Start Over You searched for: Author "Furtado, Remo H.M." Remove constraint Author: "Furtado, Remo H.M."
26 results on '"Furtado, Remo H.M."'

Search Results

1. Cardiovascular Safety of Azithromycin in Patients Hospitalized With COVID-19: A Prespecified Pooled Analysis of the COALITION I and COALITION II Randomized Clinical Trials

3. Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)–Coalition IV trial

4. Platelet Reactivity in Patients With Acute Coronary Syndromes Awaiting Surgical Revascularization

6. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial

7. Anticoagulation Strategies in Non-Critically Ill Patients Hospitalized with COVID-19: A Randomized Clinical Trial

8. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

9. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction: Subanalysis From the DECLARE-TIMI 58 Trial

10. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials

11. Long‐term mortality after acute coronary syndromes among patients with normal, mildly reduced, or reduced ejection fraction

13. Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment–Elevation Myocardial Infarction: Results of REAL-TIMI 63B

14. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial

15. Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection

16. Long‐term mortality after acute coronary syndromes among patients with normal, mildly reduced, or reduced ejection fraction.

17. Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention

18. Factors associated with actively working in the very long-term following acute coronary syndrome

19. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

20. Diabetes association with self‐reported health, resource utilization, and prognosis post‐myocardial infarction

23. Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial

25. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials.

26. Influence of proven oral therapies in the very old with acute coronary syndromes: A 15year experience

Catalog

Books, media, physical & digital resources